Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ABT-493

- PMLiVE

AbbVie to expand inflammatory and autoimmune disease portfolio with $212.5m Landos acquisition

The deal will advance the clinical development of NX-13 for patients living with ulcerative colitis and Crohn’s disease

- PMLiVE

AbbVie’s Elahere granted full FDA approval for previously-treated ovarian cancer

The company recently gained access to the therapy through its $10.1bn acquisition of ImmunoGen

- PMLiVE

AbbVie and Parvus Therapeutics collaborate to develop treatments for inflammatory bowel disease

Both companies will utilise Parvus’ Navacim Treg immune tolerisation platform technology

- PMLiVE

Merck’s pneumococcal vaccine candidate for adults shows promise in late-stage studies

V116 is designed to address the strains responsible for the majority of adult pneumococcal disease

- PMLiVE

Merck presents positive phase 3 data for Keytruda plus CRT in advanced cervical cancer

According to WHO, cervical cancer is the fourth most common cancer in women globally

- PMLiVE

Gilead shares positive real-world data for COVID-19 treatment Veklury in hospitalised patients

Results were presented at the Conference on Retroviruses and Opportunistic Infections

- PMLiVE

Innovative Trials recognised at the PMEA Awards 2023 Gala Dinner

Global patient recruitment Innovative Trials took part of the PMEA Awards gala dinner alongside the best players in the pharmaceutical industry.

Innovative Trials

- PMLiVE

Innovative Trials launches the Retention Patch Program

Innovative Trials has unveiled a new partnership with the non-profit Oliver Patch Project to boost retention in pediatric studies.

Innovative Trials

- PMLiVE

Gilead and Merus announce oncology partnership worth over $1.5bn

The companies will aim to discover dual tumour-associated antigens targeting trispecific antibodies

- PMLiVE

AbbVie gains rights to OSE’s chronic inflammation therapy in deal worth $713m

The company will gain an exclusive global license to develop, manufacture and commercialise OSE-230

- PMLiVE

AbbVie and Tentarix partner to develop oncology and immunology biologics

The collaboration will use Tentarix's proprietary platform to develop biologics against two targets

- PMLiVE

AbbVie’s Produodopa rolled out by NHS England for advanced Parkinson’s patients

The roll out follows NICE’s recommendation of the treatment in October 2023

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links